Quick Answer
BIOCRYST PHARMACEUTICALS INC reported Net Income Loss of $263.86 million for the year ending 2025.
- BIOCRYST PHARMACEUTICALS INC showed an increase of +396.9% in Net Income Loss from 2024 to 2025.
- This data is from BIOCRYST PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2009 to 2025 (17 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Over the full 17 years of available data (2009 to 2025), BIOCRYST PHARMACEUTICALS INC's Net Income Loss has grown by 2,061.6%.
- Historical annual values: Fiscal year 2025: $263.86 million | Fiscal year 2024: -$88.88 million | Fiscal year 2023: -$226.54 million | Fiscal year 2022: -$247.12 million | Fiscal year 2021: -$184.06 million | Fiscal year 2020: -$182.81 million | Fiscal year 2019: -$108.90 million | Fiscal year 2018: -$101.25 million | Fiscal year 2017: -$65.78 million | Fiscal year 2016: -$55.14 million | Fiscal year 2015: -$43.02 million | Fiscal year 2014: -$45.19 million | Fiscal year 2013: -$30.11 million | Fiscal year 2012: -$39.08 million | Fiscal year 2011: -$56.95 million | Fiscal year 2010: -$33.85 million | Fiscal year 2009: -$13.45 million.
- Data sourced from SEC EDGAR public filings as of June 23, 2026.
Last verified: